
This study conducted a retrospective review of clinical outcomes in 25 patients treated over the last 3 years with 1st‐line BRAF‐targeted therapy in a real‐world clinical setting at a UK‐based tertiary centre. The overall response rate was similar, at 64%. However, only five patients went on to receive 2nd‐line immunotherapy. In a modern‐day, real‐world setting, these patients should be counselled that only 1 in 5 are likely to receive 2nd‐line immunotherapy, and their survival times are expected to be short.
Like
Save
Share